INDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who...
Hence then, the article about lilly s olomorasib receives u s fda s breakthrough therapy designation for the treatment of previously treated kras g12c mutant advanced pancreatic cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer )
Also on site :
- Meta says automation wrongly took down No Kings and a Senate candidate’s page. It’s automating more anyway
- In 1917, a Kentucky Coal Miner Asked for a Snack ‘As Big as the Moon’; He Got an Iconic Treat That’s Still Sold Today
- 1967 Rock Hit, Covered by David Bowie Before Its Release, Is Still an All-Time Classic Rock Anthem 59 Years Later